Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ABBV crawled time : 14:15 save search
Breast Implants Market size worth $ 2.02 Billion, Globally, by 2028 at 5.22% CAGR: Verified Market Research®
Published: 2021-11-11 (Crawled : 14:15) - prnewswire.com
JNJ | News | $144.86 0.06% 2.8M
|
Health Technology
|
| O: -0.43%
H: 0.0%
C: 0.0%
ABBV | $167.2 1.8% 1.3M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
implant research market
AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis
Published: 2021-11-09 (Crawled : 14:15) - biospace.com/
ABBV | $167.2 1.8% 1.3M
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: 0.0%
rheumatoid arthritis response
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet
Published: 2021-09-09 (Crawled : 14:15) - biospace.com/
ABBV | $167.2 1.8% 1.3M
|
Health Technology
|
| O: -0.83%
H: 0.27%
C: -1.98%
GMAB | $28.6 0.25% 77K
|
Health Technology
|
| O: -1.2%
H: 0.95%
C: -0.77%
trial t-cell lancet
A $138.8 Billion Global Opportunity for Nanotechnology in Drug Delivery by 2026 - New Research from StrategyR
Published: 2021-09-03 (Crawled : 14:15) - prnewswire.com
ABBV | $167.2 1.8% 1.3M
|
Health Technology
|
| O: -0.75%
H: 0.8%
C: 0.4%
drug technology research drug delivery liver
AbbVie to Host Second-Quarter 2021 Earnings Conference Call
Published: 2021-07-07 (Crawled : 14:15) - biospace.com/
ABBV | $167.2 1.8% 1.3M
|
Health Technology
|
| O: 0.16%
H: 0.91%
C: 0.72%
conference
Global Facial Aesthetics Market to Witness $ 1.45 Billion growth during 2021-2025 | Technavio
Published: 2021-06-14 (Crawled : 14:15) - prnewswire.com
BHC | $8.735 0.87% 570K
|
Health Technology
|
| O: 0.06%
H: 0.75%
C: -0.97%
ABBV | $167.2 1.8% 1.3M
|
Health Technology
|
| O: -0.3%
H: 0.36%
C: 0.29%
ANIK | $25.62 -0.27% 13K
|
Health Technology
|
| O: -0.3%
H: 1.3%
C: -2.01%
aesthetic growth
X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia as Published in EHA Abstract
Published: 2021-05-12 (Crawled : 14:15) - globenewswire.com
ABBV | $167.2 1.8% 1.3M
|
Health Technology
|
| O: -0.03%
H: 1.0%
C: 0.1%
XFOR | $1.21 1.26% 1.1M
|
Health Technology
|
| O: -1.39%
H: 18.59%
C: 3.08%
ongoing phase 1 positive trial phase 1b phase 2b
Gainers vs Losers
| 80% | 20% |
Top 10 Gainers
AGBA | $0.7995 99.88% 73M
|
Finance
BPTH | $6.21 91.67% 58M
|
Health Technology
INVO | $1.36 78.95% 3.6M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
ALRN | $5.53 30.12% 250K
|
Health Technology
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
HOLO | $2.86 27.68% 28M
|
Your saved searches
Save your searches and get alerts when important news are released.